Prof. Huiqing Jiang | Hebei Medical University | China
Prof. Huiqing Jiang is a distinguished Professor, Chief Physician, and Doctoral Supervisor at The Second Hospital of Hebei Medical University, where he also serves as Director of the Hebei Institute of Digestive Diseases and the Hebei Key Laboratory of Digestive Diseases. A recipient of the prestigious Special Government Allowance from the State Council of China, he has made outstanding contributions to the diagnosis and treatment of digestive system diseases. His clinical expertise encompasses endoscopic diagnosis and therapeutic interventions for gastrointestinal disorders, including endoscopic resection of early cancers and polyps, stricture dilation, stent placement, treatment of esophageal varices in cirrhosis, and biliary stone extraction with pancreatic stent insertion. As a pioneer in Hebei Province, he has introduced and advanced multiple endoscopic techniques that have transformed clinical practice and improved patient outcomes. His research primarily focuses on chronic liver diseases, particularly liver fibrosis, and gastrointestinal tumors, where he has established himself as a leading authority in digestive disease research. Prof. Jiang has served as the principal investigator for two National Natural Science Foundation of China projects and has successfully completed six provincial-level projects, earning significant recognition for his innovative contributions. His work has been honored with several prestigious awards, including the First-Class Prize of the Provincial Scientific and Technological Progress Award, three Third-Class Prizes, and the Young Teachers Award from the Huo Yingdong Education Foundation. He has published an impressive 160 peer-reviewed papers, including 11 SCI-indexed articles, with his highest impact publication appearing in the Journal of Hepatology (Impact Factor 9.334). His academic influence is reflected in his citation record of 1,866 citations across 1,714 documents and an h-index of 24, showcasing his sustained scholarly impact in the field. Additionally, he has edited or co-authored 16 authoritative medical textbooks such as Internal Medicine, Diagnostics, and Clinical Hepatology, contributing extensively to medical education and training. Prof. Jiang also holds significant editorial responsibilities, serving as Associate Editor-in-Chief of Gastroenterology and Hepatology and as a board member of several core medical journals. His leadership extends to professional associations as Standing Committee Member of the Chinese Society of Digestive Endoscopy and the Endoscopist Branch of the Chinese Medical Doctor Association, and as Chairman of both the Hebei Branch of the Digestive Endoscopist Association and the Hebei Society of Gastroenterology.
Featured Publications
piR-19521 facilitates cancer stem cell-like properties by enhancing ALX4 transcription via an enhancer RNA-like mechanism in colorectal cancer. International Journal of Biological Macromolecules.
Correction to: The role of the apoptosis-related protein BCL-B in the regulation of mitophagy in hepatic stellate cells during the regression of liver fibrosis. Experimental & Molecular Medicine, 51(1), 1–13.
Identification and validation of a novel predictive signature based on hepatocyte-specific genes in hepatocellular carcinoma by integrated analysis of single-cell and bulk RNA sequencing. BMC Medical Genomics.
Development and validation of risk prediction model for bacterial infections in acute liver failure patients. European Journal of Gastroenterology & Hepatology.
Effect of oxaliplatin on the activation of hepatic stellate cells and its mechanism. Journal of Clinical Hepatology.
Development and validation of a new prognostic model for patients with acute-on-chronic liver failure in intensive care unit. World Journal of Gastroenterology.
Identification of oxidative stress-related biomarkers associated with the development of acute-on-chronic liver failure using bioinformatics. Scientific Reports.
Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer. BMC Gastroenterology.